Establishes an awareness campaign on the use of hormone replacement therapy in treating the symptoms of perimenopause and menopause

2025 Regular Session Introduced by Pete Harckham and 3 co-sponsors

The bill requires New York public health programs to provide balanced information on menopause, hormone replacement therapy, benefits, risks, side effects, and current usage recomm

SUBSTITUTED BY A10045

Summary of Bill S.8894 (2025-2026) – New York

Purpose and intent

Establishes an awareness campaign within the public health framework to inform the public about hormone replacement therapy (HRT) in the treatment of perimenopause and menopause.

The campaign aims to provide information on the symptoms of perimenopause and menopause, potential health risks, the types of HRT available, associated benefits and side effects, and current usage recommendations.

Key provisions and changes

Amends the Public Health Law to add a new paragraph (t) in subdivision 1 of section 207.

The new paragraph requires dissemination of information on:

Perimenopause and menopause symptoms.
Potential health risks associated with HRT.
Types of hormone replacement therapy available, including:
Benefits
Risks
Side effects
Current recommendations for the usage of hormone replacement therapy, along with other relevant information.

No new funding mechanisms or program administration specifics are included in the text provided; the bill focuses on the requirement to provide information and awareness.

Who or what would be affected

Public health information programs in New York state would be tasked with incorporating HRT-related information into awareness campaigns.

The target audience includes individuals experiencing perimenopause and menopause, as well as healthcare providers and the general public seeking information on HRT.

State agencies responsible for public health messaging would need to ensure accuracy, balance, and up-to-date guidance on HRT, including benefits, risks, and alternatives.

Procedural and timeline aspects

The bill was introduced in the Senate on January 13, 2026, and referred to the Committee on Women’s Issues.

It passed through committee stages and advanced to third reading by May 2026 (as reflected in the action history), with subsequent substitution and floor action indicated.

Effective date: The act would take effect on the sixtieth day after it becomes law.

Immediate authority is granted for necessary rule or regulation changes to implement the act on its effective date.

Additional notes

Co-sponsors include Jessica Scarcella-Spanton, Roxanne Persaud, Pete Harckham, and John Liu.

The text does not specify a funding source, program structure, or implementation agency for the awareness campaign; these details would likely be addressed in accompanying regulations or agency guidance if the bill becomes law.

The bill emphasizes education and information provision rather than creating a new medical service or imposing new clinical requirements.